Mark Eisenberg
Tel.: 514-340-8222 x23564
Or contact:

Tabitha Finch
Clinical Research Coordinator Team Leader
514-340-8222 x23240
Mark J. Eisenberg, MD MPH


  • Senior Investigator, Centre for Clinical Epidemiology and Community Studies, Lady Davis Institute
  • Director of the Cardiovascular Health Services Research Group, Jewish General Hospital
  • Director of the Cardiac Catheterization Laboratory, Jewish General Hospital
  • James McGill Professor of Medicine, McGill University
  • Director of the MD-PhD Program, McGill University
Dr. Eisenberg is a James McGill Professor of Medicine at McGill University and a Staff Cardiologist at the Jewish General Hospital. He is an Associate Member of the McGill Department of Epidemiology, Biostatistics, and Occupational Health. In addition to his clinical responsibilities, Dr. Eisenberg is Director of the McGill MD-PhD Program, as well as Director of the Cardiovascular Health Services Research Group of the Jewish General Hospital and a Senior Investigator at the Centre for Clinical Epidemiology and Community Studies.

Dr. Eisenberg was born in Rochester, New York. He completed a BA in Chemistry in 1980 at Cornell University, followed by an MD at the University of Rochester. After completing his MD, Dr. Eisenberg did a residency in internal medicine at McGill University, a Masters of Public Health at Harvard University, a research fellowship in echocardiography and epidemiology and a cardiology fellowship at the University of California in San Francisco. In 1995, Dr. Eisenberg completed an interventional cardiology fellowship at the Cleveland Clinic.

In 2008-2009, Dr. Eisenberg spent a year in Israel as a visiting professor in the Department of Human Metabolism and Nutrition at the Joseph H. and Belle R. Braun Hebrew University, Hadassah School of Public Health and Community Medicine. During this sabbatical, he also completed an International Master’s of Health Leadership at McGill University.

Dr. Eisenberg is married and has five children. He is fluent in English, French, and Hebrew.
Major Research Activities

Over the course of his career, Dr. Eisenberg has published over 300 articles in peer-reviewed journals and participated in multiple collaborative works.

His research team is examining the use and effectiveness of various smoking cessation pharmacotherapies with several randomized controlled trials. The Zyban as an Effective Smoking Cessation Aid (ZESCA) trial compared the efficacy of bupropion (Zyban) to that of a placebo as a means of reducing smoking rates in patients following an enzyme-positive acute coronary syndrome (ACS). The evaluation of varenicline (Champix™) in smoking cessation for patients post-acute coronary syndrome (EVITA) trial examined the efficacy and safety of varenicline for smoking cessation post-ACS. The CIHR-funded Evaluating the Efficacy of E-Cigarette use for Smoking Cessation (E3) trial assessed the efficacy of nicotine and non-nicotine e-cigarettes for smoking cessation in the general population of smokers motivated to quit. Dr. Eisenberg’s current CIHR-funded trial, titled Aggressive Smoking Cessation Therapy Post-Acute Coronary Syndrome (ASAP), aims to determine the efficacy of combining varenicline and nicotine e-cigarettes for increased smoking abstinence in patients with ACS.

Dr. Eisenberg’s research team also performs systematic reviews and meta-analyses. Recent publications concern the regulation, ethics, and efficacy of e-cigarettes for smoking cessation, impaired driving and cannabis use, and revascularization in patients with ST-segment elevation myocardial infarction and multivessel coronary disease.

In addition, Dr. Eisenberg has authored four books, the links for which are listed under the “Important Links” section of this page.
Recent Publications
Belzile-Dugas E, Eisenberg MJ. Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology. J Am Heart Assoc. 2021 Sep 21;10(18):e021686. doi: 10.1161/JAHA.121.021686. Epub 2021 Sep 6.

Razaghizad A, Windle SB, Filion KB, Gore G, Kudrina I, Paraskevopoulos E, Kimmelman J, Martel MO, Eisenberg MJ. The Effect of Overdose Education and Naloxone Distribution: An Umbrella Review of Systematic Reviews. Am J Public Health. 2021 Aug;111(8):e1-e12. doi: 10.2105/AJPH.2021.306306. Epub 2021 Jul 2.

Windle SB, Sequeira C, Filion KB, Thombs BD, Reynier P, Grad R, Ells C, Eisenberg MJ. Impaired driving and legalization of recreational cannabis. CMAJ. 2021 Apr 6;193(14):E481-E485. doi: 10.1503/cmaj.191032.

Levett JY, Windle SB, Filion KB, Cabaussel J, Eisenberg MJ. Meta-Analysis of Complete versus Culprit-Only Revascularization in Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Disease. Am J Cardiol. 2020 Nov 15;135:40-49. doi: 10.1016/j.amjcard.2020.08.030.

Eisenberg MJ, Hébert-Losier A, Windle SB, Greenspoon T, Brandys T, Fulop T, Nguyen T, Elkouri S, Montigny M, Wilderman I, Bertrand OF, Bostwick JA, Abrahamson J, Lacasse Y, Pakhale S, Cabaussel J, Filion KB. Effect of E-Cigarettes Plus Counseling vs Counseling Alone on Smoking Cessation: A Randomized Clinical Trial. JAMA. 2020 Nov 10;324(18):1844-54. doi: 10.1001/jama.2020.18889.
Dr. Mark Eisenberg’s research focuses on the primary and secondary prevention of cardiovascular disease, with topics ranging from interventional cardiology to broad public health issues such as smoking and obesity. His most recent completed randomized clinical trial, E3, was published in JAMA (see citation under ‘Recent Publications’). The results of the E3 trial suggest that nicotine e-cigarettes are moderately efficacious for smoking cessation.
Important Links

McGill University Division of Cardiology

McGill University Division of Clinical Epidemiology

Support research at the Lady Davis Institute - Jewish General Hospital